Cardiovascular Effects of an Immunosuppressive Agent Cyclosporin A

Abstract

Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in transplant recipients. Recently, the calcineurin inhibitor CsA has been employed in vivo and in vitro to examine the role of calcineurin in the signal transduction leading to cardiac hypertrophy. A cell culture study demonstrated the inhibitory effect of CsA on cytokine production by cardiac myxoma cells, the most common primary tumor of the heart. This review discusses recent data on the cardiovascular effects of CsA.

Keywords

Cyclosporin A hypertension hyperlipidemia diabetes cardiac hypertrophy calcineurin cardiac myxoma cytokine

References

Kahan

B.D.

1989. Cyclosporine. N. Engl. J. Med. 321:1725.

Cohen

D.J.

Loertscher

Rubin

M.F.

. 1984. Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 10:667.

Curtis

J.J.

Luke

R.G.

Dubovsky

. 1986. Cyclosporine in therapeutic doses increase renal allograft vascular resistance. Lancet. 2:477.

Bellet

Cabrol

and Sassano

. 1985. Systemic hypertension after cardiac transplantation: Effect of cyclosporine on the renin-angiotensin system. Am. J. Cardiol. 56:927.

Luke

R.G.

1986. Hypertension in renal transplant recipients. Kidney Int. 31:1024.

Markell

M.S.

and Friedman

E.A.

. 1989. Hyperlipidemia after organ transplantation. Am. J. Med. 87:61N.

Miles

A.M.

Sumrani

N.B.

Horowitz

. 1998. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 65:380.

Rao

Jacob

C.K.

and Shastry

J.C.M.

. 1992. Post-transplant diabetes mellitus: A retrospective study. Nephrol. Dial. Transplant. 7:1039.

Sumrani

N.B.

Delaney

Ding

. 1991. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation 51:343.

10.

Hricik

D.E.

Bartucci

M.R.

Moir

E.J.

. 1991. Effects of steroid withdrawal on post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 51:374.

11.

Yashikawa

Nakai

Ohmori

. 1988. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am. J. Kidney Dis. 12:11.

12.

Friedman

E.A.

Shyh

T.P.

Beyer

M.M.

. 1985. Post-transplant diabetes in kidney transplant recipients. Am. J. Nephrol. 5:196.

13.

Sussman

M.A.

Lim

H.W.

Gude

. 1998. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281:1690.

14.

Luo

Shyu

K. G.

Gualberto

. 1998. Carcineurin inhibitors and cardiac hypertrophy (Letter). Nat. Med. 4:1092.

15.

Ding

Price

R.L.

Borg

T.K.

. 1999. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ. Res. 84:729.

16.

Zhang

Kowal

R.C.

Rusnak

. 1999. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ. Res. 84:722.

17.

Meguro

Hong

and Asai

. 1999. Cyclosporine attenuates pressure- overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84:735.

18.

Force

Rosenzweig

Choukroun

. 1993. Calcineurin inhibitors and cardiac hypertrophy. Lancet 353:1290.

19.

Sakamoto

Sakamaki

Kanda

. 1997. Immunosuppressive drugs inhibit the production of interleukin-6 and interleukin-8 in cultured cardiac myxoma cells. Res. Commun. Molec. Pathol. Pharmacol. 97:60.

20.

Conte

Canton

A.D.

Sabbatini

. 1989. Acute cyclosporine renal dysfunction reversed by dopamine infusion in health subjects. Kidney Int. 36:1086.

21.

Moss

N.G.

Powell

S.L.

and Falk

R. J.

. 1985. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in enervated kidneys in rats. Proc. Natl. Acad. Sci. USA. 82:8222.

22.

Perico

N.A.

Benigni

Zoja

. 1986. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am. J. Physiol. 251:F581.

23.

Pfeischifter

and Ruegg

U.T.

. 1987. Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem. J. 278:883.

24.

Garr

M.D.

and Paller

M.S.

. 1990. Cyclosporine augments renal but not systemic vascular reactivity. Am. J. Physiol. 258:F211.

25.

Cottet-Maire

Avdonin

P.V.

Roulet

. 2001. Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment. Br. J. Pharmacol. 132:909.

26.

Hansen

J.M.

Johansen

N.J.

Mollerup

H.M.

. 1999. Effects of nitric oxide blockage and cyclosporin A on cardiovascular and renal function in normal man. J. Hypertens. 17:1707.

27.

Curtis

J.J.

Laskow

D.A.

Julian

B.A.

. 1988. Nifedipine is a more effective renal vasodilater than captopril in cyclosporine (CSA) transplant (TX) hypertension. Kidney Int. 35:512.

28.

Ballantyne

C.M.

Podet

E.J.

Patsch

W.P.

. 1989. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262:53.

29.

Webb

A.T.

Reaveley

D.A.

O'Donnel

. 1993. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 341:268.

30.

Al Rayyes

Wallmark

and Floren

C.-H.

. 1996. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by 25%. Hepatology 24:613.

31.

Al Rayyes

Wallmark

and Floren

C.-H.

. 1997. Reversal of cyclosporine inhibited low density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Hepatology 25:991.

32.

Gunnarsson

Lundgren

Magnusson

. 1980. Steroid diabetes: A sign of overtreatment with steroids in the renal graft recipient? Scand. J. Urol. Nephrol. 54:135.

33.

McGeown

M.G.

Douglas

J.F.

Brown

W.A.

. 1980. Advantages of low-dose steroids from the day after renal transplantation. Transplantation 29:287.

34.

Ost

1984. Effects of cyclosporine on prednisolone metabolism. Lancet 1:451.

35.

Gillison

S.G.

Bartlett

S.T.

and Curry

D.L.

. 1989. Synthesis-secretion coupling of insulin: Effect of cyclosporine. Diabetes 38:465.

36.

Andersson

Borg

Mallberg

. 1984. Long-term effects of cyclosporine A on cultured mouse pancreatic islets. Diabetologia 17:66.

37.

Eun

H.M.

Pak

C.Y.

Kim

C.J.

. 1987. Role of cyclosporine A in macromolecular synthesis of beta cells. Diabetologia 36:952.

38.

Hahn

H.J.

Dunger

Laube

. 1986. Reversibility of the acute effect of cyclosporine A on pancreatic β cells of Wistar rats. Diabetolodia 29:489.

39.

Hahn

H.J.

Laube

Lucke

. 1986. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 41:22.

40.

Rao

Luo

and Hogan

P.G.

. 1997. Transcription factors of the NFAT family: Regulation and function. Annu. Rev. Immunol. 15:707.

41.

Molkentin

J.D.

J.-R.

Antos

C.L.

. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:214.

42.

Colucci

W.S.

Schoen

F.J.

and Braunwald

. 1997. Primary tumors of the heart. In Heart Disease: A Textbook of Cardiovascular Medicine (5th ed). Braunwald

, ed. W.B. Saunders Co. Philadelphia, p. 1464.

43.

Markel

M.L.

Waller

B.F.

and Armstrong

W.F.

. 1987. Cardiac myxoma: A review. Medicine. 66:114.

44.

Reynen

Cardiac myxomas. 1995. N. Engl. J. Med. 333:1610.

45.

Hirano

Tage

Yasukawa

. 1987. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA. 84:228.

46.

Garcia

J.E.

Lopez

A.M.

de-Cabo

M.R.

. 1999. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Medicators Inflamm. 8:253.